{"filing":{"accession_number":"0001829126-26-006688","cik":"0001979414","ticker":"NTHI","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"neonctechnologies_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626006688/neonctechnologies_8k.htm"},"events":[{"id":11962,"run_id":10525,"accession_number":"0001829126-26-006688","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO212, marking the first international regulatory clearance for the Company's lead clinical-stage drug candidate following Phase 1 completion. This represents a material regulatory milestone that advances the development pathway and expands the Company's clinical footprint internationally. While not a traditional earnings release, exec change, M\u0026A activity, or other specifically enumerated event type, this regulatory approval is material to investors assessing the Company's clinical development progress and commercial prospects for a key asset.","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8686,"accession_number":"0001829126-26-006688","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO212, marking the first international regulatory clearance for the Company's lead clinical-stage drug candidate following Phase 1 completion. This represents a material regulatory milestone that advances the development pathway and expands the Company's clinical footprint internationally. While not a traditional earnings release, exec change, M\u0026A activity, or other specifically enumerated event type, this regulatory approval is material to investors assessing the Company's clinical development progress and commercial prospects for a key asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:01:36.717692+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8686,"accession_number":"0001829126-26-006688","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO212, marking the first international regulatory clearance for the Company's lead clinical-stage drug candidate following Phase 1 completion. This represents a material regulatory milestone that advances the development pathway and expands the Company's clinical footprint internationally. While not a traditional earnings release, exec change, M\u0026A activity, or other specifically enumerated event type, this regulatory approval is material to investors assessing the Company's clinical development progress and commercial prospects for a key asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:01:36.717692+00:00","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-06-18"}]}